Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapyDiseaseEndometrial CancerSubgroupICD10C54.1MeSHEndometrial NeoplasmsSequencePORTEC-3: CISP50/Radiation, Endometrial Ca, adj. A (PID922) -|- PACL175/CRBP5, adj, B (PID923)ChemotherapyChemo-substanceCarboplatinCisplatinPaclitaxelChemo-substanceCarboplatinCisplatinPaclitaxelChemo-substanceCarboplatinCisplatinPaclitaxelChemo-substanceCarboplatinCisplatinPaclitaxelNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfatePotassium chlorideNo. Substances67Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHypertensionInfectionsNeuropathyNeutropeniaThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDe Boer SDiseaseEndometriumkarzinom, Stadium I-III, postoperativ, ECOG 0-2OriginDepartment of Radiation Oncology, Leiden University Medical Center, Netherlands PORTEC-3Protocols in Revision 2 protocols foundProtocols under revision.Cisplatin 50 / Radiation, Endometrial Cancer adjuvant, Part A (PID922 V1.1)Paclitaxel 175 / Carboplatin 5, Endometrial Cancer adjuvant, Part B (PID923 V1.1)
